Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Summary

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT) as initial therapy.

Eligibility

INCLUSION CRITERIA:

1. Participants must be 18 years or older, at the time of signing the ICF.
2. Participant must have documented diagnosis of MM according to the IMWG diagnostic criteria.
3. Participant must have one or more of the following measurable disease criteria: (a) Serum M-protein level ≥1.0 g/dL, (b) Urine M-protein level ≥ 200 mg/24 h, (c)Serum immunoglobulin FLC ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda FLC ratio.
4. Participant must be deemed ineligible for ASCT while also having adequate organ function for CAR-T cell treatment.
5. Participant is a candidate to receive at least one of the regimens (IsaVRd or DRd) as determined by the Investigator.
6. ECOG performance status Grade of 0 to 2.
7. Participant must have adequate organ and bone marrow function.

EXCLUSION CRITERIA:

1. Participant has active or prior CNS or meningeal involvement of MM.
2. Participant has primary amyloidosis, active plasma cell leukemia (≥5% circulating plasma cells), Waldenström macroglobulinemia, or POEMS syndrome.
3. Participant has significant neurological or psychiatric condition posing risk or impairing evaluation.
4. Participant has any other significant medical condition that increases unacceptable risk, interferes with therapy delivery, or confounds evaluation.
5. Participant has a history of a prior non-haematologic malignancy unless the participant has been disease-free with no evidence of recurrence for ≥ 2 years.
6. Participant has a history of haematologic malignancies, other than MM, regardless of remission status.
7. Participant is positive for any of the following:

   1. HIV: Known to be seropositive for HIV (including any history of HIV).
   2. Chronic or active hepatitis B.
   3. Active hepatitis C: Hepatitis C infection.
   4. Additional local requirements for the testing for infectious diseases and exclusions of applicable participants should be followed per local regulations.
8. Participant has clinically significant cardiovascular disease.
9. Participant has COPD with an FEV1 \< 50% of predicted normal.
10. Additional exclusion for participants who are planned to receive IsaVRd as induction: Participant has peripheral neuropathy Grade 4, Grade 3, Grade 2, or Grade 1 with pain.

Conditions2

Interventions8

Locations45 sites

Find trials near these locations

Related trials

• AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) — AstraZeneca
• A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) — AstraZeneca
• A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. — Alexion Pharmaceuticals, Inc.
• A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) — AstraZeneca
• A Study of AZD0120 in Autoimmune Diseases — AstraZeneca
• A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE — AstraZeneca
• A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) — Nanjing IASO Biotechnology Co., Ltd.
• A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. — Karyopharm Therapeutics Inc

Browse More Trials